Skip to main content

Featured

BoC Set to Hike Into a Weak Economy: What It Means for You

  Canadian Money Brief • Feature Monday, October 26, 2026 • Written ahead of the 9:45 a.m. ET decision on Wednesday, Oct. 28 The Bank of Canada is about to do something that looks backwards. Jobs are disappearing, the housing market is sluggish, and yet money markets and most economists expect the central bank to raise its key rate on Wednesday. If it happens, your budget gets squeezed from two directions at once: higher borrowing costs and a shakier job market. The short version • Expected move: +0.25 point to 2.50% on Oct. 28, up from 2.25% • Reuters poll: 56% of economists (19 of 34) call for a hike, and a majority see one more by end of March • Why now: energy-driven inflation (3.1% in September) and a bank worried it spreads • The catch: 68,300 jobs lost in September , unemployment at 6.5% Why would the bank hike when the economy is wobbling? Reuters reports the Bank of Canada is expected to raise its rate as a pre-emptive strike: the goal is to stop an oil-driven jump in p...
Post a Comment
Read more

article

Labels

U.S. Drug Tariffs: A Looming Crisis for Global Supply Chains


The U.S. government's decision to impose tariffs on pharmaceutical imports has sent shockwaves through the healthcare industry, raising concerns about potential drug shortages and skyrocketing costs. Industry leaders warn that these tariffs could disrupt critical supply chains, affecting the availability of essential medications and medical devices.

Johnson & Johnson CEO Joaquin Duato has voiced concerns over the impact of these tariffs, advocating for tax incentives instead of trade barriers to support domestic drug manufacturing Warns Tariffs Could Disrupt U.S. Drug Supply Chains](https://www.theglobeandmail.com/investing/markets/stocks/LLY-N/pressreleases/31903548/jj-ceo-jnj-warns-tariffs-could-disrupt-us-drug-supply-chains/). Meanwhile, a recent survey indicates that healthcare executives anticipate significant price hikes, with some predicting an 18% increase in medical equipment costs and a 33% rise in critical device prices.

The American Hospital Association has urged the administration to reconsider these tariffs, emphasizing the reliance of U.S. healthcare providers on international sources for life-saving drugs and supplies. Experts caution that while the tariffs aim to boost domestic production, the transition could take years, leaving patients vulnerable to shortages and inflated prices.

As pharmaceutical companies scramble to adjust their supply chains, the industry faces an uncertain future. Whether these tariffs will achieve their intended goal or exacerbate existing challenges remains to be seen. Policymakers must weigh the long-term consequences carefully to ensure that patient care and affordability are not compromised.

Labels:

Comments

Post a Comment